{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:00:37Z","timestamp":1777118437048,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jogoh.2025.102929","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:38:06Z","timestamp":1741174686000},"page":"102929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of mifepristone on uterine fibroids: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"54","author":[{"given":"Lili","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogoh.2025.102929_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jogoh.2025.102929_bib0002","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.18203\/2320-1770.ijrcog20232731","article-title":"A study on the effect of mifepristone on uterine fibroids","volume":"12","author":"Yadav","year":"2023","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0003","first-page":"39","article-title":"Mifepristone in fibroids: comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule","volume":"12","author":"Shaikh","year":"2021","journal-title":"J Midlife Health"},{"key":"10.1016\/j.jogoh.2025.102929_bib0004","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1210\/endrev\/bnab039","article-title":"Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment","volume":"43","author":"Yang","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jogoh.2025.102929_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2017.09.004","article-title":"Epidemiology and risk factors of uterine fibroids","volume":"46","author":"Pavone","year":"2018","journal-title":"Best practice & research Clinical obstetrics & gynaecology"},{"key":"10.1016\/j.jogoh.2025.102929_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18370\/2309-4117.2022.63.8-18","article-title":"\u041c\u0456\u043e\u043c\u0430 \u043c\u0430\u0442\u043a\u0438: \u0441\u0438\u043d\u0442\u0435\u0437 \u0441\u0443\u0447\u0430\u0441\u043d\u0438\u0445 \u0437\u043d\u0430\u043d\u044c: \u043e\u0433\u043b\u044f\u0434 \u043b\u0456\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u0438","author":"Plaksiieva","year":"2022","journal-title":"Reprod Endocrinol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0007","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.2174\/1381612826666210101152820","article-title":"Highlights on medical treatment of uterine fibroids","volume":"27","author":"Angioni","year":"2021","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jogoh.2025.102929_bib0008","doi-asserted-by":"crossref","first-page":"272","DOI":"10.18231\/j.ijogr.2023.056","article-title":"Efficacy of different doses of mifepristone in the management of uterine leiomyoma in a tertiary care centre","volume":"10","author":"Marimuthu","year":"2023","journal-title":"Indian Journal of Obstetrics and Gynecology Research"},{"key":"10.1016\/j.jogoh.2025.102929_bib0009","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/med.21311","article-title":"The unique pharmacological characteristics of mifepristone (RU486): from terminating pregnancy to preventing cancer metastasis","volume":"34","author":"Chen","year":"2014","journal-title":"Med Res Rev"},{"key":"10.1016\/j.jogoh.2025.102929_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9946224","article-title":"Oral administration of Mifepristone combined with ultrasound-guided radiofrequency ablation in treating patients with uterine fibroids: efficacy, safety, and alternations of inflammatory cytokines, adhesion molecules, and growth factors","volume":"2021","author":"Hou","year":"2021","journal-title":"J Nanomater"},{"key":"10.1016\/j.jogoh.2025.102929_bib0011","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.4103\/jfmpc.jfmpc_467_20","article-title":"A prospective interventional study to evaluate the effects of medical therapy (Mifepristone 25 mg) on the management of uterine fibroids","volume":"9","author":"Gupta","year":"2020","journal-title":"J Family Med Prim Care"},{"key":"10.1016\/j.jogoh.2025.102929_bib0012","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/1933719116671002","article-title":"Genomic and nongenomic effects of Mifepristone at the cardiovascular level: a review","volume":"24","author":"Feiteiro","year":"2017","journal-title":"Reprod Sci"},{"key":"10.1016\/j.jogoh.2025.102929_bib0013","doi-asserted-by":"crossref","first-page":"888","DOI":"10.18203\/2320-1770.ijrcog20230782","article-title":"A study on role of low dose mifepristone in the management of fibroid in reproductive age group women","volume":"12","author":"Rani","year":"2023","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0014","doi-asserted-by":"crossref","first-page":"397","DOI":"10.33545\/gynae.2021.v5.i1g.843","article-title":"Role of low dose mifepristone in management of uterine fibroid","volume":"5","author":"Bharti Maheshwari","year":"2021","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0016","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/clinchem\/42.11.1777","article-title":"Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates","volume":"42","author":"Schlaeppi","year":"1996","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jogoh.2025.102929_bib0017","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/81.2.107","article-title":"Publication bias and dissemination of clinical research","volume":"81","author":"Begg","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogoh.2025.102929_bib0018","first-page":"1154","article-title":"Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India","volume":"137","author":"Kulshrestha","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jogoh.2025.102929_bib0019","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pog.2010.02.002","article-title":"Evolution of uterine leiomyoma after treatment with mifepristone. Randomized clinical trial","volume":"53","author":"Carbonell","year":"2010","journal-title":"Prog Obstet Ginecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0021","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s13224-016-0861-7","article-title":"Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids","volume":"66","author":"Kapur","year":"2016","journal-title":"J Obstet Gynecol India"},{"key":"10.1016\/j.jogoh.2025.102929_bib0022","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.fertnstert.2013.08.039","article-title":"Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis","volume":"100","author":"Shen","year":"2013","journal-title":"Fertil Steril"},{"key":"10.1016\/j.jogoh.2025.102929_bib0023","first-page":"227","article-title":"[Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata]","volume":"33","author":"Sun","year":"1998","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/j.jogoh.2025.102929_bib0024","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas A randomized controlled trial","volume":"112","author":"Esteve","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pog.2009.11.001","article-title":"5 mg versus 10 mg mifepristone daily in the treatment of leiomyoma: a randomised clinical trial","volume":"53","author":"Carbonell Esteve","year":"2010","journal-title":"Prog Obstet Ginecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0026","article-title":"Effects of low dose oral mifepristone on uterine fibroids","volume":"9","author":"Saxena","year":"2019","journal-title":"Indian Obstetrics and Gynaecology"},{"key":"10.1016\/j.jogoh.2025.102929_bib0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.32553\/ijmbs.v4i8.1392","article-title":"Role of low dose of mifepristone in management of fibroid in perimenopausal women: a comparative study","volume":"4","author":"Rani","year":"2020","journal-title":"Int J Med Biomed Stud"},{"key":"10.1016\/j.jogoh.2025.102929_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.33545\/gynae.2020.v4.i1b.447","article-title":"Low dose mifepristone in the conservative management of leiomyomas: a prospective randomised controlled trial","volume":"4","author":"Srimathi","year":"2020","journal-title":"Int J Clin Obstet Gynaecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0029","first-page":"14","article-title":"Clinical utility of mifepristone: apprising the expanding horizons","author":"Karena","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jogoh.2025.102929_bib0030","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.18203\/2320-1770.ijrcog20184958","article-title":"Study the effect of mifepristone on fibroid and uterine volume","volume":"7","author":"Seher","year":"2018","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0031","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jogoh.2025.102929_bib0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Carbonell Esteve","year":"2012","journal-title":"Int J Women's Health"},{"key":"10.1016\/j.jogoh.2025.102929_bib0033","doi-asserted-by":"crossref","first-page":"9990","DOI":"10.14260\/jemds\/2015\/1444","article-title":"Role of low dose mifepristone in the treatment of symptomatic fibroid uterus: a double control randomized control trial","volume":"4","author":"Lal","year":"2015","journal-title":"J Evol Med Dent Sci"},{"key":"10.1016\/j.jogoh.2025.102929_bib0034","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.ogx.0000368148.48878.7a","article-title":"Mifepristone for treatment of uterine leiomyoma: a prospective randomized placebo controlled trial","volume":"65","author":"Engman","year":"2010","journal-title":"Obstet Gynecol Survey"},{"key":"10.1016\/j.jogoh.2025.102929_bib0035","first-page":"130","article-title":"The use of Mifepristone for treatment of the uterine fibroma","volume":"36","author":"Esteve","year":"2010","journal-title":"Rev Cuba Obstet Ginecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/649030","article-title":"Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","author":"Carbonell","year":"2013","journal-title":"ISRN Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0037","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0038","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJWH.S42770","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"5","author":"Esteve","year":"2013","journal-title":"Int J Women's Health"},{"key":"10.1016\/j.jogoh.2025.102929_bib0039","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Australian and New Zealand Journal of Obstetrics and Gynaecology"},{"key":"10.1016\/j.jogoh.2025.102929_bib0040","first-page":"130","article-title":"Mifepristona para tratamiento del fibroma uterino","volume":"36","author":"Carbonell Esteve","year":"2010","journal-title":"Rev Cuba Obstet Ginecol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0041","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.jogoh.2025.102929_bib0042","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/IJWH.S33125","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","author":"Carbonell","year":"2013","journal-title":"Int J Women's Health"},{"key":"10.1016\/j.jogoh.2025.102929_bib0043","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.14260\/jemds\/2016\/937","article-title":"Effectiveness and safety of Mifepristone in different dose (10 mg and 25 mg) for the treatment of uterine fibroids and to evaluate quality of life","volume":"5","author":"Rai","year":"2016","journal-title":"J Evol Med Dent Sci"}],"container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784725000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784725000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:02:05Z","timestamp":1772913725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468784725000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2468784725000261"],"URL":"https:\/\/doi.org\/10.1016\/j.jogoh.2025.102929","relation":{},"ISSN":["2468-7847"],"issn-type":[{"value":"2468-7847","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mifepristone on uterine fibroids: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Gynecology Obstetrics and Human Reproduction","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogoh.2025.102929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102929"}}